Table 1 Demographics and baseline characteristics of the prior AMPH subgroup (n = 41) and overall safety population (n = 420)
Variable, n (%) | Prior AMPH subgroup | Overall safety population | |||
|---|---|---|---|---|---|
Placebo | LDX (all doses) | Placebo | LDX (all doses) | ||
n = 2 | n = 39 | n = 62 | n = 358 | ||
Sex | Male | 0 | 20 (51.3) | 32 (51.6) | 196 (54.7) |
Female | 2 (100.0) | 19 (48.7) | 30 (48.4) | 162 (45.3) | |
Race | White | 1 (50.0) | 38 (97.4) | 48 (77.4) | 301 (84.1) |
Non-white | 1 (50.0) | 1 (2.6) | 14 (22.6) | 57(15.9) | |
Ethnicity | Hispanic/Latino | 0 | 1 (2.6) | 6 (9.7) | 34 (9.5) |
Non-Hispanic/Non-Latino | 2 (100.0) | 38 (97.4) | 56 (90.3) | 324 (90.5) | |
CGI-S at baseline | Moderately ill | 1 (50.0) | 12 (30.8) | 27 (43.5) | 115 (32.1) |
Markedly ill | 1 (50.0) | 17 (43.6) | 25 (40.3) | 195 (54.5) | |
Severely/extremely ill | 0 | 10 (25.6) | 10 (16.1) | 48 (13.4) | |